1887

Abstract

We hypothesized that the large global variations in the prevalence of macrolide resistance in Treponema pallidum are related to differences in population-level macrolide consumption. The hypothesis was tested by, at a country-level, regressing the peak prevalence of macrolide resistance against the national macrolide consumption in the year prior to this, controlling for the year of the resistance prevalence estimate. A strong association was found between the per capita consumption of macrolides and macrolide resistance (coefficient 0.7, 95 % confidence interval 0.2–0.12, P=0.009).

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000885
2018-12-06
2020-01-22
Loading full text...

Full text loading...

/deliver/fulltext/jmm/68/2/119.html?itemId=/content/journal/jmm/10.1099/jmm.0.000885&mimeType=html&fmt=ahah

References

  1. Grimes M, Sahi SK, Godornes BC, Tantalo LC, Roberts N et al. Two mutations associated with macrolide resistance in Treponema pallidum: increasing prevalence and correlation with molecular strain type in Seattle, Washington. Sex Transm Dis 2012;39:954 [CrossRef][PubMed]
    [Google Scholar]
  2. Müller EE, Paz-Bailey G, Lewis DA. Macrolide resistance testing and molecular subtyping of Treponema pallidum strains from southern Africa. Sex Transm Infect 2012;88:470–474 [CrossRef][PubMed]
    [Google Scholar]
  3. Wu H, Chang SY, Lee NY, Huang WC, Wu BR et al. Evaluation of macrolide resistance and enhanced molecular typing of Treponema pallidum in patients with syphilis in Taiwan: a prospective multicenter study. J Clin Microbiol 2012;50:2299–2304 [CrossRef][PubMed]
    [Google Scholar]
  4. Yang CJ, Tang HJ, Chang SY, Hsieh SM, Lee KY et al. Comparison of serological responses to single-dose azithromycin (2 g) versus benzathine penicillin G in the treatment of early syphilis in HIV-infected patients in an area of low prevalence of macrolide-resistant Treponema pallidum infection. J Antimicrob Chemother 2016;71:775–782 [CrossRef][PubMed]
    [Google Scholar]
  5. Grillová L, Pĕtrošová H, Mikalová L, Strnadel R, Dastychová E et al. Molecular typing of Treponema pallidum in the Czech Republic during 2011 to 2013: increased prevalence of identified genotypes and of isolates with macrolide resistance. J Clin Microbiol 2014;52:3693–3700 [CrossRef][PubMed]
    [Google Scholar]
  6. Hicks LA, Chien YW, Taylor TH, Haber M, Klugman KP. Outpatient antibiotic prescribing and nonsusceptible Streptococcus pneumoniae in the United States, 1996-2003. Clin Infect Dis 2011;53:631–639 [CrossRef][PubMed]
    [Google Scholar]
  7. Bronzwaer SL, Cars O, Buchholz U, Mölstad S, Goettsch W et al. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg Infect Dis 2002;8:278–282 [CrossRef][PubMed]
    [Google Scholar]
  8. Riedel S, Beekmann SE, Heilmann KP, Richter SS, Garcia-de-Lomas J et al. Antimicrobial use in Europe and antimicrobial resistance in Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis 2007;26:485–490 [CrossRef][PubMed]
    [Google Scholar]
  9. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005;365:579–587 [CrossRef][PubMed]
    [Google Scholar]
  10. Kenyon C, Buyze J, Wi T. Antimicrobial consumption and susceptibility of Neisseria gonorrhoeae: a global ecological analysis. Frontiers in Medicine (In Press)
    [Google Scholar]
  11. Baquero F. Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption?. J Chemother 1999;11:35–43 [CrossRef][PubMed]
    [Google Scholar]
  12. Bergman M, Huikko S, Pihlajamäki M, Laippala P, Palva E et al. Effect of macrolide consumption on erythromycin resistance in Streptococcus pyogenes in Finland in 1997-2001. Clin Infect Dis 2004;38:1251–1256 [CrossRef][PubMed]
    [Google Scholar]
  13. Sanford JP, Gilbert DN, Sande MA. In The Sanford Guide to Antimicrobial Therapy, Pocket sized version. Dallas, TX; Sperryville, VA: Antimicrobial Therapy; 2018
    [Google Scholar]
  14. Crokaert F, Hubloux A, Cauchie P. A phase I determination of azithromycin in plasma during a 6-week period in normal volunteers after a standard dose of 500mg once daily for 3 days. Clin Drug Investig 1998;16:161–166 [CrossRef][PubMed]
    [Google Scholar]
  15. Bergman M, Huikko S, Huovinen P, Paakkari P, Seppala H. Finnish study group for antimicrobial r. macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 2006;50:503646
    [Google Scholar]
  16. Stamm LV. Global challenge of antibiotic-resistant Treponema pallidum. Antimicrob Agents Chemother 2010;54:583–589 [CrossRef][PubMed]
    [Google Scholar]
  17. Kiddugavu MG, Kiwanuka N, Wawer MJ, Serwadda D, Sewankambo NK et al. Effectiveness of syphilis treatment using azithromycin and/or benzathine penicillin in Rakai, Uganda. Sex Transm Dis 2005;32:1–6 [CrossRef][PubMed]
    [Google Scholar]
  18. Marra CM, Colina AP, Godornes C, Tantalo LC, Puray M et al. Antibiotic selection may contribute to increases in macrolide-resistant Treponema pallidum. J Infect Dis 2006;194:1771–1773 [CrossRef][PubMed]
    [Google Scholar]
  19. Kenyon C, Colebunders R, Voeten H, Lurie M. Peak HIV prevalence: a useful outcome variable for ecological studies. Int J Infect Dis 2013;17:e286e288 [CrossRef][PubMed]
    [Google Scholar]
  20. Šmajs D, Paštěková L, Grillová L. Macrolide Resistance in the Syphilis Spirochete, Treponema pallidum ssp. pallidum: can we also expect macrolide-resistant yaws strains?. Am J Trop Med Hyg 2015;93:678–683 [CrossRef][PubMed]
    [Google Scholar]
  21. European Centre for Disease Prevention and Control Antimicrobial resistance surveillance in Europe 2015. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) Stockholm: ECDC; 2015
    [Google Scholar]
  22. Godfrey C, Thigpen MC, Crawford KW, Jean-Phillippe P, Pillay D et al. Global HIV antiretroviral drug resistance: a perspective and report of a national institute of allergy and infectious diseases consultation. J Infect Dis 2017;216:S798–S800 [CrossRef][PubMed]
    [Google Scholar]
  23. Tyczkowska-Sieron E, Gaszynski W, Tyczkowski J, Glowacka A. Analysis of the relationship between fluconazole consumption and non-C. albicans Candida infections. Med Mycol 2014;52:758–765 [CrossRef][PubMed]
    [Google Scholar]
  24. Ben-Ami R, Olshtain-Pops K, Krieger M, Oren I, Bishara J et al. Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection. Antimicrob Agents Chemother 2012;56:2518–2523 [CrossRef][PubMed]
    [Google Scholar]
  25. Gjestland T. An epidemiological investigation of the natural course of the syphilitic infection based upon a restudy of the Boeck-Bruusgaard material. Acta Derm Venereol 1955;35:
    [Google Scholar]
  26. Xin D, Mi Z, Han X, Qin L, Li J et al. Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China. Antimicrob Agents Chemother 2009;53:2158–2159 [CrossRef][PubMed]
    [Google Scholar]
  27. Xiao YH, Giske CG, Wei ZQ, Shen P, Heddini A et al. Epidemiology and characteristics of antimicrobial resistance in China. Drug Resist Updat 2011;14:236–250 [CrossRef][PubMed]
    [Google Scholar]
  28. Baquero F, Coque TM, Cantón R. Allodemics. Lancet Infect Dis 2002;2:591–592 [CrossRef][PubMed]
    [Google Scholar]
  29. European Centre for Disease Prevention and Control Syphilis. Annual Epidemiological Report For 2015 Stockholm: ECDC; 2017
    [Google Scholar]
  30. Lu H, Li K, Gong W, Yan L, Gu X et al. High frequency of the 23S rRNA A2058G mutation of Treponema pallidum in Shanghai is associated with a current strategy for the treatment of syphilis. Emerg Microbes Infect 2015;4:e10 [CrossRef][PubMed]
    [Google Scholar]
  31. Kenyon C. We need to consider collateral damage to resistomes when we decide how frequently to screen for chlamydia/gonorrhoea in PrEP cohorts. AIDS 2018;1 [CrossRef][PubMed]
    [Google Scholar]
  32. Kenyon CR, de Baetselier I, Crucitti T. Does gonorrhoea screening intensity play a role in the early selection of antimicrobial resistance in men who have sex with men (MSM)? A comparative study of Belgium and the United Kingdom. F1000Res 2018;7:569 [CrossRef][PubMed]
    [Google Scholar]
  33. Coenen S, Gielen B, Blommaert A, Beutels P, Hens N et al. Appropriate international measures for outpatient antibiotic prescribing and consumption: recommendations from a national data comparison of different measures. J Antimicrob Chemother 2014;69:529–534 [CrossRef][PubMed]
    [Google Scholar]
  34. Morgan DJ, Okeke IN, Laxminarayan R, Perencevich EN, Weisenberg S. Non-prescription antimicrobial use worldwide: a systematic review. Lancet Infect Dis 2011;11:692–701 [CrossRef][PubMed]
    [Google Scholar]
  35. Goossens H, Ferech M, Coenen S, Stephens P. European surveillance of antimicrobial consumption project G. comparison of outpatient systemic antibacterial use in 2004 in the United States and 27 European countries. Clin Infect Dis 2007;44:1091–1095
    [Google Scholar]
  36. Klein EY, van Boeckel TP, Martinez EM, Pant S, Gandra S et al. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci USA 2018;115:E3463E3470 [CrossRef][PubMed]
    [Google Scholar]
  37. Chow EP, Howden BP, Walker S, Lee D, Bradshaw CS et al. Antiseptic mouthwash against pharyngeal Neisseria gonorrhoeae: a randomised controlled trial and an in vitro study. Sex Transm Infect 2017;93:88–93 [CrossRef][PubMed]
    [Google Scholar]
  38. Lipsitch M, Siber GR. How can vaccines contribute to solving the antimicrobial resistance problem?. MBio 2016;7:e0042816 [CrossRef][PubMed]
    [Google Scholar]
  39. Mitchell SJ, Engelman J, Kent CK, Lukehart SA, Godornes C et al. Azithromycin-resistant syphilis infection: San Francisco, California, 2000-2004. Clin Infect Dis 2006;42:337–345 [CrossRef][PubMed]
    [Google Scholar]
  40. Serisier DJ. Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respir Med 2013;1:262–274 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000885
Loading
/content/journal/jmm/10.1099/jmm.0.000885
Loading

Data & Media loading...

Supplements

Supplementary File 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error